Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UK MHRA Pilot To Explore Benefits Of Standalone Inspections For Pharmacovigilance Service Providers

This article was originally published in SRA

Executive Summary

The UK Medicines and Healthcare Products Regulatory Agency has launched a pilot to ascertain whether the introduction of a new standalone program, under which it would inspect pharmacovigilance service providers, could cut inspection costs incurred by drug companies that use these third-party organizations and also save agency resources.

Advertisement

Related Content

UK MHRA Adapts Inspections Program To Account For Increase In Pharmacovigilance Outsourcing
Advertisement
UsernamePublicRestriction

Register

PS118381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel